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Abstract: α-Synuclein (αS) is an intrinsically disordered and highly dynamic protein involved in
dopamine release at presynaptic terminals. The abnormal aggregation of αS as mature fibrils into
intraneuronal inclusion bodies is directly linked to Parkinson’s disease. Increasing experimental
evidence suggests that soluble oligomers formed early during the aggregation process are the most
cytotoxic forms of αS. This study investigated the uptake by neuronal cells of pathologically relevant
αS oligomers and fibrils exploiting a range of conformation-sensitive antibodies, and the super-
resolution stimulated emission depletion (STED) microscopy. We found that prefibrillar oligomers
promptly penetrate neuronal membranes, thus resulting in cell dysfunction. By contrast, fibril
docking to the phospholipid bilayer is accompanied by αS conformational changes with a progressive
release of A11-reactive oligomers, which can enter into the neurons and trigger cell impairment. Our
data provide important evidence on the role of αS fibrils as a source of harmful oligomers, which
resemble the intermediate conformers formed de novo during aggregation, underling the dynamic
and reversible nature of protein aggregates responsible for α-synucleinopathies.
Keywords: synucleinopathies; protein aggregation; amyloid; toxic oligomers; Lewy bodies; PD;
protein misfolding; neurodegeneration
1. Introduction
The abnormal aggregation of αS, a 14 kDa intrinsically disordered protein impli-
cated in neurotransmitter release at presynaptic terminals, is associated with the onset
and progression of Parkinson’s disease (PD) and other debilitating neurodegenerative
conditions collectively referred to as α-synucleinopathies [1]. Intraneuronal inclusions
called Lewy bodies and neurites, primarily consisting of αS fibrils, are the major neu-
ropathological hallmark of such diseases [2,3]. However, there is increasing evidence that
metastable oligomeric assemblies, formed during the early phases of αS aggregation, play
a crucial role in neuronal injury [4–10]. Despite their prominent role in the pathogenesis
of α-synucleinopathies, the isolation and structural characterization of αS oligomers is
extremely difficult because of their instability and transient nature. αS fibrils have also
been demonstrated to be harmful, and their neurotoxicity has been associated with the
disruption of plasma membrane integrity [11], with the perturbation of ionic homeostasis,
as well as with the imbalance of cellular proteostasis systems [12]. Moreover, αS fibrils
were reported to possess a high propagation propensity and to amplify the aggregation of
endogenous αS by seeding [13–17].
The association of pathogenic αS species with lipid membranes is actually considered
to be a primary event in the cascade of neuronal dysfunction in PD [8–11]. We have
previously described the mechanisms of membrane perturbation and neuronal damage
triggered by a range of well-characterized and stable αS aggregates, referred to as type-B*
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oligomers (OB*), short fibrils (SF), and long fibrils (LF), prepared under physiological
conditions, according to developed protocols [5,7,10]. OB*, which possess a rudimentary
cross-β structure and high solvent-exposed hydrophobicity [8,10], have been previously
shown to be harmful to neuronal cells because of their ability to interact aberrantly with
neurons and to rapidly penetrate cells [8–10]. Such oligomers can further aggregate and
form fibrils, whose neurotoxicity has been associated with the release of oligomeric-like
conformers, that are highly toxic to neuronal cells [5,7,10].
Taking advantage of a range of well-characterized conformation-sensitive antibodies
selectively targeting αS conformers, and the super-resolution of STED microscopy, here
we provide relevant evidence on the ability of SF to release small oligomers. These are
structurally similar to OB* and penetrate human iPSC-derived dopaminergic neurons
and primary rat cortical neurons. Moreover, we observed that the conformation-sensitive
antibodies were able to bind to OB* and SF with a selective specificity, thus dramatically
reducing their inherent neurotoxicity.
2. Materials and Methods
2.1. Generation of αS OB* and SF
The monomer of humanαS (M) was expressed in E. coli BL21 cells (Agilent, Santa Clara,
CA, USA) and then purified as previously reported [7]. OB* were generated by passing
monomeric αS through a 0.22 µm cutoff filter and subsequently by incubating the protein
at a concentration of 12 mg/mL in PBS buffer (pH 7.4) at 37 ◦C in stationary mode for 24 h,
as reported previously [7,8]. SF samples were obtained by incubating monomeric αS at
70 µM in PBS buffer with a pH of 7.4 with 0.01% NaN3 at 37 ◦C under constant shaking for
4–6 days, and then by incubating 10 µM of these preformed fibrils with 100 µM monomeric
αS for 13–15 h under quiescent conditions with subsequent sonication, as described previ-
ously [10]. The concentration of αS aggregates was estimated by measuring the absorbance
at 275 nm using ε275 = 5600 M−1 cm−1 after the addition of 4 M guanidinium chloride.
2.2. Dot-Blot Assay of αS Conformers
To probe αS conformers, 0.7 µg of each sample (2 µL) was spotted onto a polyvinyli-
dene fluoride (PVDF) membrane. The membranes were blocked for 30 min with 1.0%
bovine serum albumin in TBS/TWEEN 0.1% and then incubated overnight at 4 ◦C with
rabbit polyclonal anti-oligomer A11 antibodies (1:1000, Thermo Fisher Scientific, Waltham,
MA, USA), rabbit polyclonal anti-amyloid fibrils OC antibodies (1:1000, Sigma-Aldrich,
St. Louis, MO, USA), mouse monoclonal anti-aggregated αS 5G4 antibodies (1:1800,
Sigma-Aldrich), or with mouse monoclonal anti-αS 211 antibodies (1:1800, Santa Cruz
Biotechnology, Dallas, TX, USA). The immunolabelled blots were finally incubated with the
proper secondary antibodies conjugated with horseradish peroxidase (Abcam, Cambridge,
UK) and then detected by using a Pierce™ ECL Western Blotting Substrate (Thermo Fisher
Scientific, Waltham, MA, USA) and ImageQuant™ TL software (GE Healthcare, Chicago,
IL, USA).
2.3. Cell Cultures
Human SH-SY5Y neuroblastoma cells (A.T.C.C., Manassas, VA, USA) were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM), F-12 Ham with 25 mM 4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) and NaHCO3 (1:1) supplemented
with 10% fetal bovine serum (FBS), 1.0 mM glutamine and 1.0% penicillin and strepto-
mycin solution in a 5.0% CO2 humidified atmosphere at 37 ◦C and grown until 80% of
confluence, as previously reported [9]. The cells were authenticated and tested to be free
from mycoplasma contaminations.
Primary rat cortical neurons (Thermo Fisher Scientific) were plated and maintained in
Neurobasal medium (Thermo Fisher Scientific) plus 0.5 mM GlutaMAX (Gibco, Thermo
Fisher Scientific) and 2% (v/v) B-27 serum-free complement (Gibco, Thermo Fisher Scientific)
at 37 ◦C in a 5.0% CO2 humidified atmosphere. Every 3–4 days, the medium was partially
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replaced and the experiments were performed 12–16 days after plating, as previously
reported [18,19].
Human iPSC-derived dopaminergic neurons were obtained from iPSC-derived dopamin-
ergic neuron progenitors (Axol Bioscience, Cambridge, UK). The cells were plated on 12-well
plates containing glass coverslips coated with poly-D-lysine plus surebond-XF solution and
led to maturation according to manufacturer’s instructions. The analyses were performed
14–18 days after plating, as previously described [10].
2.4. Analysis of the Interaction with and Internalization into Neuronal Cells of αS Conformers
SH-SY5Y cells seeded on glass coverslips were incubated for 60 min with αS con-
formers (0.3 µM) and then stained with 5.0 µg/mL Alexa Fluor 633-conjugated wheat
germ agglutinin (Thermo Fisher Scientific), as previously reported [20]. Following a fix-
ing step with 2% (v/v) paraformaldehyde, and a permeabilization phase with glycerol at
3.0% (v/v), αS was detected with rabbit polyclonal anti-oligomer A11 antibodies (1:250),
rabbit polyclonal anti-amyloid fibrils OC (1:800), or with mouse monoclonal anti-αS 211
antibodies (1:250), then with Alexa-Fluor-488-conjugated anti-rabbit or mouse secondary
antibodies (1:1000, Thermo Fisher Scientific). The detection of the fluorescence emission
was obtained by double excitation at 633 nm and 488 nm through a TCS SP8 scanning
confocal microscopy system (Leica Microsystems, Mannheim, Germany). A series of 1.0 µm
thick optical sections (1024 × 1024 pixels) was taken through the cell depth for each sample
using a Leica Plan Apo 63× oil immersion objective and projected as a single composite
image by superimposition. The confocal microscope was set and maintained constant at
optimal detector gain and laser powers.
2.5. Analysis of the Mitochondrial Status with the MTT Assay
The mitochondrial functionality of the different αS species was evaluated in SH-SY5Y
cells seeded in 96-well plates by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. M, OB* and SF (0.3 µM concentration) were added to the culture
medium of SH-SY5Y cells for 24 h. In a set of experiments, OB* and SF were added to the
cell culture medium for 30 min and then rabbit polyclonal anti-oligomer A11 antibodies or
rabbit polyclonal anti-amyloid fibrils OC antibodies, or mouse monoclonal anti-aggregated
αS 5G4 antibodies, or mouse monoclonal anti-αS 211 antibodies were added (in a 1:2.5
molar ratio) for 24 h. The cell culture medium was then removed, cells were washed with
PBS, and the MTT assay was performed as previously reported [10,18,19]. Cell viability
was expressed as the percentage of MTT reduction in treated cells as compared to untreated
cells, unless otherwise indicated.
2.6. Evaluation of Caspase-3 Activity
The activation of caspase-3, which is the primary effector caspase in the apoptotic
pathway, was assessed in SH-SY5Y cells by confocal microscopy. αS species were added at
0.3 µM to the cell culture medium for 0, 1, 3, 5 and 24 h. In a set of experiments, SH-SY5Y
cells were treated with OB* and SF and, after 30 min, the A11, OC, 5G4 and 211 antibodies
were added to the cell culture medium for 24 h. After the incubation, the cell culture
medium was removed and the FAM-FLICA Caspase 3/7 solution (Immunichemistry
Technologies, LLC, Bloomington, MN, USA) was added as previously described [10].
The detection of the fluorescence emission was obtained by exciting the laser line at
488 nm through the confocal microscopy described in a previous paragraph. The different
fluorescence intensities relative to activated caspase-3 were plotted versus the time elapsed
after the addition of αS aggregates to the culture medium, and the resulting kinetic plots
were fitted by means of a single exponential (1) or a sigmoidal (2) functions of the forms:
F(t) = F(eq) + A exp(−kt) (1)
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where F(t) corresponds to the intracellular fluorescence at time t as a percentage of that ob-
served in untreated cells, F(0) is the same fluorescence at 0 h, F(eq) is the same fluorescence
at the apparent equilibrium (time ∞), A is the amplitude of the fluorescence change as a
percentage of that observed in untreated cells, k is the apparent rate constant in s−1 and B
is the slope of the sigmoidal function at time t.
2.7. Confocal Microscopy Analysis of αS Species In Vitro
OB* and SF (0.3 µM) were incubated in culture medium for 0 and 24 h at 37 ◦C
in wells containing a glass coverslip in the absence of cells. The coverslips were then
fixed with 2% (v/v) paraformaldehyde, blocked with 0.5% BSA to avoid non-specific
antibody reactions, and incubated for 30 min at 37 ◦C with rabbit anti-oligomer A11
polyclonal antibodies (1:2500) or with mouse monoclonal anti-αS 211 antibodies (1:2000),
then for 30 min with Alexa Fluor 514-conjugated anti-rabbit or anti-mouse secondary
antibodies (1:2000, Thermo Fisher Scientific), as reported previously [10]. The detection of
the fluorescence emission was obtained by exciting the laser line at 514 nm through the
confocal microscope described previously.
2.8. Western Blotting of αS Species in Cellular Fractions
SH-SY5Y cells were treated with SF and OB*at 0.3 µM for 24 h. Membrane and
cytoplasmic fractions were obtained as previously described with minor modifications [21].
Briefly, the cells were homogenized in PBS containing 9.0% sucrose with three freeze–thaw
cycles, 5.0 s sonication on ice and centrifugation at 700× g for 10 min at 4 ◦C. The membrane
fraction was pelleted by supernatant centrifugation at 110,000× g for 1 h at 4 ◦C and
separated from the cytoplasmic one. The protein content in the fractions was measured by
the method of Bradford [22]. Thirty µg of each fraction were run on 4–20% Mini-PROTEAN
TGX precast gels (Bio-Rad, Hercules, CA, USA) and the separated proteins were blotted
onto a Supported Nitrocellulose Membrane (Bio-Rad). The blotted membranes were then
blocked in 1.0% (w/v) BSA in TBS-Tween (0.1% Tween 20 in 20 mM Tris–HCl buffer, pH
7.5, containing 100 mM NaCl) and then incubated with mouse monoclonal anti-αS 211
antibodies (1:250, Santa Cruz Biotechnology). After extensive washing, the membranes
were incubated with peroxidase-conjugated anti-mouse secondary antibodies (Abcam) for
1 h and the immunolabelled bands were detected using a Pierce™ ECL Western Blotting
Substrate (Thermo Fisher Scientific) and ImageQuant™ TL software (GE Healthcare).
2.9. STED Microscopy Analysis of αS Species in Neurons
Primary rat cortical neurons and human iPSC-derived dopaminergic neurons were
treated with OB* and SF at 0.3 µM for 24 h. After treatment, cortical neurons were stained
with 0.01 mg/mL wheat germ agglutinin, Tetramethylrhodamine Conjugate (TMR, Thermo
Fisher Scientific) and αS was detected with mouse monoclonal anti-αS 211 antibodies
(1:125) and Alexa Fluor 514-goat anti-mouse secondary antibodies (1:500) as previously
reported [10]. Dopaminergic neurons were stained with mouse anti-MAP-2 antibodies
(1:400, Abcam) and rabbit polyclonal anti-oligomer A11 antibodies (1:250) and then with
Alexa-Fluor-568-conjugated anti-rabbit secondary antibodies (1:500, Thermo Fisher Sci-
entific) and Alexa-Fluor-514-conjugated anti-mouse secondary antibodies (1:500, Thermo
Fisher Scientific). Fluoromount-G™ (Thermo Fisher Scientific) was used as mounting
medium. Then, the STED images (i.e., z-stacks acquired along three directions: x, y, and z
axes) were acquired by using an SP8 STED 3X confocal microscopy (Leica Microsystems).
The detection of the fluorescence emission was obtained after double excitation at 550 nm
or 568 nm, and 514 nm through a white light laser (WLL). STED xyz images were acquired
in bidirectional mode. The emitted fluorescence of TMR, Alexa Fluor 568 and Alexa Fluor
514 were collected from 564 to 599 nm, from 575 to 595 nm, and from 532 to 551 nm, re-
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spectively. Frame sequential acquisition was applied to avoid fluorescence overlap. Gated
pulsed-STED was applied to Alexa-Fluor 514 fluorophore, with a gating between 0.3 to
6 ns, to avoid the collection of reflection and autofluorescence. A Leica HC PL APO CS2
100×/1.40 oil STED White objective was used. Images were collected at 0.1 µm intervals
with a Z stack of approximately 5 µm and deconvolved with Huygens Professional software
(Scientific Volume Imaging B.V., Hilversum, The Netherlands; version 18.04), as previously
reported [10].
2.10. Statistical Analysis
All data were presented as a means ± standard error of mean (S.E.M). Comparisons
between the different groups were performed by the Student t-test or by ANOVA followed
by Bonferroni’s post-comparison test by using GraphPad Prism 7.0 software (San Diego,
CA, USA).
3. Results
3.1. αS Oligomers Permeabilize Neuronal Membrane Triggering Cell Dysfunction
Due to the transient nature and high structural heterogeneity of intermediates formed
during αS aggregation, in this study we employed a set of conformation-sensitive antibod-
ies to target the different αS conformers by immunoblot analysis. Specifically, we assessed
the degree of specificity of A11, OC and 5G4 antibodies for the well-characterized and
stable αS M, OB* and SF, prepared under physiological conditions according to developed
protocols [5,7,10]. The A11 antibodies have been previously reported to recognize a struc-
tural epitope present in oligomeric assemblies of different proteins and peptides, which is
absent in monomers and fibrils [23]. The OC antibodies are specific for amyloid fibrillar
species without labelling monomers and oligomers [24], whereas the 5G4 antibodies were
raised against every αS aggregated species [25,26].
The dot-blot analysis showed that the A11 and OC antibodies can selectively detect αS
oligomers and fibrils, respectively (Figure 1A). In contrast, the 5G4 antibodies recognized
both αS aggregates, with a very low cross-reaction with the monomeric protein. The equal
loading of each αS conformer was assessed by the monoclonal conformation-insensitive
anti-αS 211 antibodies, which are specific for residues 121–125 at the C-terminal domain of
human αS (Figure 1A).
We then evaluated the ability of the conformation-sensitive antibodies to detect αS
conformers interacting with the plasma membrane (extracellular αS) and being internalized
into the cytosol of fixed human SH-SY5Y neuroblastoma cells (intracellular αS), which were
previously incubated for 1 h with culture medium containing αS species at a concentration
of 0.3 µM. The plasma membranes (red channel) were counterstained with wheat germ
agglutinin, and αS species (green channel) with the aforementioned antibodies (A11,
OC and 211), and subsequently analyzed by confocal scanning microscopy (Figure 1B).
A very low green fluorescent signal was observed both intracellularly and extracellularly
with A11, OC and 211 antibodies in cells exposed to αS M (Figure 1B,C). Notably, the
A11 antibodies showed a significant increase in intracellular αS-derived fluorescence (by
956 ± 130%) in neuronal cells exposed to OB* relative to untreated cells, taken as 100%.
On the contrary, a low intracellular αS A11-reactivity was shown in cells treated with SF
(by 241 ± 51%) (Figure 1B,C). In addition, the OC antibodies selectively targeted SF at the
surface of the neuronal membranes (by 4891 ± 320%), without any positive reactivity in
cells exposed to OB* (Figure 1B,D). In contrast, the 211 antibodies were able to recognize
both OB* and SF interacting with the surface of the plasma membrane (by 669 ± 128%
and 4641 ± 227%, respectively) (Figure 1B,D) and being internalized by neuronal cells
(by 1055 ± 106% and 293 ± 60%, respectively) (Figure 1B,C). These results are in good
agreement with previously reported data [8,10], suggesting that OB* have a much higher
propensity to permeabilize the neuronal membrane with respect to SF, which remained
largely localized at the membrane surface.
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*** p  <  0.001). 
We then evaluated whether the permeabilizing ability of αS species was related to 
their capacities to induce mitochondrial dysfunction. The ability of SH-SY5Y cells to re-
duce the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) signifi-
cantly decreased (by 28 ± 2%), following a 24 h treatment with 0.3 μM OB*, according to 
our previous results [27]. SF, which have been found to be largely bound to the outer 
leaflet of the neuronal membranes at 1 h of exposure, were able to significantly decrease 
Figure 1. (A) Dot-blot analysis of αS conformers labelled with conformation-sensitive antibodi s A11, OC, and 5G4,
and conformation-inse sitive 211 antibodies specific for human αS. (B) Representative confocal images of SH-SY5Y cells
exposed to αS species at 0.3µM for 1 h. Red fluorescence shows the cell membranes revealed with wheat germ agglutinin.
Green fluorescence indicates the αS species labelled with the indicated antibodies. (C,D) Histograms reporting the semi-
quantitative analysis of intracellular (C) and extracellular (D) αS fluorescence expressed as the percentage observed in
untreated cells, taken as 100%. (E) MTT reduction in SH-SY5Y cells exposed to αS species at 0.3µM for 24 h. Error bars
indicate S.E.M. The statistical analysis was made by one-way ANOVA followed by Bonferroni’s multiple comparison test
relative to untreated cells (* p < 0.05, ** p < 0.01, *** p < 0.001).
We then evaluated whether the permeabilizing ability of αS species was related to their
capacities to induce mitochondrial dysfunction. The ability of SH-SY5Y cells to reduce the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) significantly decreased
(by 28 ± 2%), following a 24 h treatment with 0.3 µM OB*, according to our previous
results [27]. SF, which have been found to be largely bound to the outer leaflet of the
neuronal membranes at 1 h of exposure, were able to significantly decrease the MTT
reduction (by 23 ± 2%) at longer time of exposure, whereas M appeared to be harmless
(Figure 1E).
To clarify whether the toxicity of αS conformers depends on the time of exposure to
neuronal cells, we monitored over time the ability of OB* and SF to cause the activation of
caspase-3, the most common marker of apoptosis [28]. OB* were more rapid, with respect
to SF, in inducing caspase-3 activation, with a half-maximal time of apoptotic activation
occurring after 3 h of treatment with OB* and after 6 h with SF (Figure 2).
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lengths of time (1, 3, 5 and 24 h) with M, OB* and SF at 0.3 µM. Untreated cells are also shown. The
fluorescence signals are expressed as the percentage of the values for untreated cells, taken as 100%.
The kinetic plots report the caspase-3 derived fluorescence versus time following αS addition to the
cell medium. The continuous lines through the data represent the best fits to a single-exponential
function for OB* (green line), and a sigmoidal function for SF (blue line). Error bars indicate S.E.M.
The statistical analysis was made by one-way ANOVA followed by Bonferroni’s multiple comparison
test relative to untreated cells (* p < 0.05, *** p < 0.001).
Indeed, the maximal toxicity of SF was observed following 24 h of cell exposure, when
the fluorescent signals were expressed as the percentage of the values for untreated cells,
taken as 100%. This evidence suggests that OB* cause an immediate cell dysfunction,
whereas fibrils induce gradual deleterious effects on neuronal cells.
3.2. Conformation-Sensitive Antibodi s Att nuate the Toxicity of αS Aggregates
We then exploited the conformation-sensitive antibodies in competition experiments to
investigate the mechanisms by which SF cause a delayed neuronal dysfunction. Specifically,
we compared the activation of the apoptotic pathway in SH-SY5Y cells exposed to αS
conformers and A11, OC, 5G4 and 211 antibodies (in a αS:Ab molar ratio of 1:2.5) for 24 h.
Similarly to the results of the time course analysis, OB* and, to a lesser extent, SF, induced
a significant caspase-3 activation (by 305 ± 25% and 251 ± 8%, respectively, compared to
untreated cells) in the absence of antibodies (Figure 3A,B). Notably, the addition of A11
antibodies significantly prevented apoptosis activation induced by both OB* and SF (by
132 ± 40% and 124 ± 13%, respectively). In contrast, the OC antibodies markedly rescued
the caspase-3 activation evoked by SF (by 114 ± 14%), without affecting OB* cytotoxicity
(Figure 3A,B). Accordingly, a protective effect of 5G4 antibodies against apoptotic death
triggered by OB* and SF (by 98 ± 41% and 88 ± 20%, respectively) was also observed. The
211 antibodies significantly reduced the activation of the apoptotic pathway induced by
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OB* (by 111 ± 39%), with a minor inhibition of caspase-3 activation induced by SF (by
59 ± 18%; Figure 3A,B).
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Figure 3. (A) Representative confocal images showing caspase-3 activity in SH-SY5Y cells treated
with αS aggregates at 0.3 µM and A11, OC, 5G4 and 211 antibodies (in a 1:2.5 molar ratio) for
24 h. (B) The histogram reports a semi-quantitative analysis of caspase-3 activity expressed as the
percentage of untreated cells represented in Figure 2, taken as 100%. (C) MTT reduction in SH-SY5Y
cells treated with αS aggregates (0.3 µM) and with A11, OC, 5G4 and 211 antibodies (in a 1:2.5 molar
ratio) for 24 h. Error bars indicate S.E.M. The statistical analysis was made by one-way ANOVA
followed by Bonferroni’s multiple comparison test relative to untreated cells (* p < 0.05, ** p < 0.01,
*** p < 0.001), or to cells treated with the same αS species without antibodies (◦ p < 0.05, ◦◦ p < 0.01,
and ◦◦◦ p < 0.001).
A consistent trend was obtained with the analysis of metabolic impairment by the
MTT assay (Figure 3C). Indeed, the A11 antibodies significantly prevented the cytotoxicity
induced by both OB* (by 27 ± 8%) and SF (by 22 ± 6%). In contrast, the OC antibodies
significantly prevented the neurotoxicity of SF (by 14 ± 4%), but not that of OB* (Figure 3C).
The 5G4 antibodies significantly inhibited the OB*-induced mitochondrial dysfunction (by
14 ± 5%), with only a minor and not significant effect against SF (Figure 3C). Finally, the
presence of the conformation-insensitive 211 antibodies significantly rescued the metabolic
impairment induced by OB* (by 18 ± 7%), with a slight but not significant effect against
the fibrillar species (Figure 3C). Taken together, these results indicate that A11 antibodies
can significantly rescue the neurotoxicity of both oligomeric and fibrillar αS conformers,
whereas the OC antibodies can inhibit only the fibril-induced cellular dysfunction. These
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data also suggest that A11 antibodies can bind OB*-like oligomers released by SF, thus
preventing apoptosis in neuronal cells surrounded by fibrils.
3.3. αS Fibrils Progressively Release Oligomers In Vitro and In Vivo
To analyze the possible leakage of A11-reactive oligomers from fibrils, we incubated
αS aggregates in the culture medium in the absence of cells on a glass coverslip for 24 h at
37 ◦C. Then, the αS species were labelled with the conformation-sensitive A11 antibodies,
as well as with the conformation-insensitive 211 antibodies. The emitted fluorescence was
detected at 514 nm excitation line by the confocal scanning microscopy system (Figure 4).
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and membrane (mem) fractions purified from SH-SY5Y cells treated for 24 h with SF or OB* at 0.3µM.
αS species were then probed with conformation-insensitive anti-αS 211 antibodies (Original Western
Blot Figure see Figure S1).
Small dots of αS-derived oligomers were counted using ImageJ software after setting
constant thresholds for every image, and excluding fibrillar species from the particle counts.
Both antibodies revealed the presence of a homogeneous population of small and globular
oligomers in freshly prepared OB* samples (at time 0 h) and in OB* samples incubated for
24 h at 37 ◦C (Figure 4A, arrowheads in the right image magnifications), with the amount
of puncta remaining constant over time (~8.4 × 10−2 puncta/µm2) (Figure 4C). On the con-
trary, the A11-reactive aggregates were substantially absent in freshly prepared SF samples
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(at time 0 h) (Figure 4B, left image magnification), and appeared after 24 h of incubation at
37 ◦C (Figure 4B, arrowhead in the right image magnification). Specifically, the amount of
oligomeric puncta significantly increased at 24 h (~5.5 × 10−2 puncta/µm2) (Figure 4C),
suggesting a release of oligomeric conformers by mature fibrils over time. Accordingly,
after a 24 h incubation of SF sample in cell culture medium, the conformation-insensitive
211 antibodies detected the appearance of a population of small green fluorescent dots
(Figure 4B, arrowhead in the right upper image magnification), likely oligomeric puncta
(Figure 4C), together with the presence of fibrillar species (Figure 4B, arrowhead in the
right lower image magnification).
We then explored whether the release of oligomers from αS fibrils was also evident in
different subcellular compartments of neuronal cells. After a 24 h treatment with OB* or SF,
SH-SY5Y cells were collected and fractionated to isolate membrane and cytosolic fractions.
The cellular fractions were then analyzed by using the mouse monoclonal 211 antibody and
western blotting assay (Figure 4D). The membrane fraction of cells treated with SF showed
a smear with a continuous of bands at the top of the lane and two intense bands at ~35 KDa
and ~60 KDa (indicated by arrowheads) and some weaker bands at lower molecular weight.
In contrast, the cytosolic sample contained only a milder band at ~60 kDa (indicated by
arrowhead), suggesting that a low amount of small-size αS was internalized in SF-treated
cells (Figure 4D). Both fractions of cells treated with OB* showed a similar pattern with
a smear at the top of the gel and three clearer bands at ~35 KDa, ~60 KDa and ~70 kDa
(indicated by arrowheads). However, the cytosolic fraction showed higher amounts of
internalized αS than the membrane one (Figure 4D). These results indicate a gradual
leakage of small species from fibrils bound to the plasma membranes, which can insert into
the lipid bilayer and reach the intracellular compartment of neuronal cells.
3.4. The Penetration of αS Oligomers into Cortical and Dopaminergic Neurons by STED Microscopy
To better characterize the subcellular structures of αS species bound to the plasma
membrane and internalized into the neurons, we took advantage of the nanometric pre-
cision of the super-resolution STED microscopy. Primary rat cortical neurons treated
with OB* for 24 h showed a large number of green-fluorescent puncta, labelled with the
conformation-insensitive anti-αS 211 antibodies, both outside and inside the cells (Figure 5).
These assemblies were small and globular in shape (Figure 5A, arrowheads in the left and
right image magnifications). According to the above reported evidence, neurons exposed to
SF for 24 h showed αS fibrillar species bound to the external side of the plasma membrane
(Figure 5A, arrowhead in the right image magnification). The same images also show a
range of small and globular intracellular αS species, possessing a morphology that was
very similar to that of OB* (Figure 5A, arrowhead in the left image magnification). We also
probed the nature of the αS species able to penetrate into human iPSC-derived dopamin-
ergic neurons, a relevant PD model, by using the conformation-sensitive A11 antibodies
(Figure 5B). STED images revealed a conspicuous A11-positive signal in neurons treated
with both OB* and SF for 24 h (Figure 5B, arrowheads in the image magnifications), strongly
indicating the presence of αS oligomeric conformers similar to OB* inside dopaminergic
neurons treated with SF.
To gain mechanistic details into the binding of αS aggregates to the neuronal mem-
branes and their internalization into the cells, we performed a z-stack analysis to obtain
the 3D reconstruction of the cortical and dopaminergic neurons treated with OB* and SF
(Figure 5C).
The mouse monoclonal 211 antibodies revealed the presence of oligomeric assemblies
bound to the outer leaflet of the plasma membrane and internalized into the cytosol in
cortical neurons treated with OB* (Figure 5C, upper left image). By contrast, cortical neu-
rons exposed to SF presented elongated aggregates attached to the extracellular side of the
membrane, along with intracellular species showing a globular morphology similar to that
of the aggregates observed inside neurons exposed to OB* (Figure 5C, lower left image). In
addition, by using the conformation-sensitive and oligomer-specific A11 antibody, we ob-
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served the presence of oligomeric assemblies inserted into the lipid bilayer and internalized
into the cytosol of dopaminergic neurons treated with SF, as well as with OB* (Figure 5C,
lower and upper right images, respectively). Overall, these data provide relevant evidence
that the αS fibrils release small oligomers bearing membrane-disrupting properties, which
are crucial to enter deeply into the bilayer interior and inside the affected neurons.
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4. Discussion
αS prefibrillar oligomers are considered to play a prominent role in the massive loss of
dopaminergic neurons responsible for the onset and progression of PD [4,5,29,30]. Despite
the increasing relevance given to αS oligomeric assemblies for their ability to induce
neuronal dyshomeostasis, many findings support the toxic capacity of mature fibrils [31];
indeed, the exposure of neuronal cells to such assemblies induces the aggregation of the
endogenous αS and the formation of inclusions that are morphologically and biochemically
similar to those found in the brain of PD patients [13–17]. When different αS aggregates
were injected into the mouse striatum to determine their ability to induce PD-related
phenotypes, β-sheet rich oligomers, referred to as OB*, were found to produce a small but
significant loss of dopaminergic neurons in the substantia nigra (SN). The injection of short
β-sheet fibrils (SF), however, produced the most robust PD-like phenotypes, including
the reduction of striatal dopamine terminals, the massive loss of dopaminergic neurons
in SN, and evident motor-behavior defects [17]. Accordingly, the aggregation of αS into
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insoluble fibers accumulated in Lewy bodies has been associated with the degeneration of
dopaminergic neurons in SN [13,32–34].
Recent evidence obtained in relevant neuronal models indicates that OB* rapidly
induce membrane perturbation, associated with calcium dyshomeostasis and production
of reactive oxygen species, whereas SF are toxic after prolonged times of binding to the
membrane [7–10,35–38]. The mechanism of interaction between αS oligomers/fibrils
and lipid membranes has been extensively investigated, as it is a crucial event in PD
pathophysiology [30,31,39,40]. Relevant studies indicated that OB* expose the disordered
lipophilic N-terminus of monomer subunits, which anchors oligomers into the membrane,
thus facilitating the insertion of the rigid oligomer core deeply into the hydrophobic
interior of the membrane [8,9,30]. On the contrary, the burying of lipophilic N-terminus of
monomers within non-toxic αS oligomers referred to as OA*, precludes their insertion in
the interior of the bilayer [8,30]. However, this issue needs further investigation, both in
terms of formation of mature fibrils from oligomeric conformers and dissolution of fibrils
into soluble and harmful oligomers upon the interaction with phospholipid bilayers.
In this work, we took advantage of a range of well-characterized conformation-
sensitive antibodies, able to selectively target the specific conformations of misfolded
oligomers and fibrils, and the super-resolution STED microscopy, to give further insights to
our previously reported evidence on the capability of αS fibrils to release oligomeric species,
both in vitro and on the neuronal bilayer [10]. Here, we found that the ability of OB* to
cause neuronal toxicity is strongly associated with their rapid and massive adsorption onto
the plasma membrane and internalization into the cytosol, occurring already after 1 h upon
their addition to the cell culture medium.
In contrast, the preformed SF remain mainly localized at the outer leaflet of the
phospholipid membrane after prolonged exposure to cortical and dopaminergic neurons,
as revealed at high resolution by STED microscopy. The presence of αS oligomeric species
similar to OB* inside the cells upon 24 h of treatment with SF strongly suggests that the
cytotoxicity of SF cannot be associated with their superficial interaction with neuronal
membranes, but rather to their ability to dissolve in membrane-disrupting oligomers, which
can penetrate neurons. Accordingly, western blotting analysis and biological read-outs
collectively show that the toxic effects of the fibrils correlate with the ability of the released
oligomers to be internalized into the cytoplasm, causing a massive caspase-3 activation
and mitochondrial dysfunction. In particular, our results indicate that αS species with
a β-sheet conformation and solvent-exposed hydrophobic surfaces may affect neuronal
viability, although at different times of exposure and with distinct levels of toxicity. Taking
advantage of STED microscopy and the conformation-sensitive A11 antibody, which are
specific for ‘soluble prefibrillar oligomers’ [23], we found that the species able to penetrate
dopaminergic neurons were A11-positive in all cases, not only when the cells were facing
OB*, but also SF, that are A11-negative per se.
Furthermore, in a cell-free condition, SF were found to release A11-positive species
over time. These results agree with the previously described capability to disaggregate
of αS fibers incubated in vitro under near-physiological conditions (pH 7.4, 37 ◦C) in
monomer-free buffer, thus leading to the release of small oligomeric assemblies [5]. More-
over, the ability of αS and also β2-microglobulin fibrils to fragment into toxic oligomeric
conformers has been observed in vitro upon mild pH acidification [41,42]. Low pH is also
characteristic of cellular organelles like lysosomes, a condition that could enhance the
release of small oligomers from intraneuronal deposits, possibly able to spread to nearby
cells [41]. Importantly, soluble, highly stable, and potentially toxic annular αS oligomers
were previously reported to be released upon a mild detergent treatment from glial cy-
toplasmic inclusions obtained from brain tissues of patients affected by multiple system
atrophy [43]. Accordingly, it was also shown that amyloid beta (Aβ) fibrils accumulated
in senile plaques in the brain of Alzheimer’s disease (AD) patients, can resolubilize into
A11-positive oligomers sharing biophysical and toxic properties with those formed in the
very early phases of Aβ aggregation [44]. This evidence is also consistent with the obser-
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vation of the leakage of Aβ oligomers from fibrils in the mouse brain [45]. In particular,
the toxicity observed in a mouse model overexpressing the Aβ peptide was proportional
to the quantity of oligomers released from amyloid plaques. Furthermore, those plaques
were neighbored by oligomeric Aβ aberrantly interacting with synapses and contributing
to their loss [45].
Taken together, our results support the claim that fibrils formed by different proteins
release oligomers, that can, in turn, contribute to the toxicity associated with fibril spreading,
and reinforce the idea that protein aggregates responsible for misfolding diseases such as α-
synucleinopathies are highly dynamic and can interconvert each other on lipid membrane
surfaces under specific microenvironmental conditions. Thus, both αS oligomers and
fibrils are involved in neurodegeneration, with mature fibers acting as a source of soluble
oligomers, which are the toxic moiety promptly affecting neuronal cells.
Our experimental data also suggest that antibodies against αS aggregates, directly
interacting with such species, or preventing the release of toxic oligomers from mature
fibrils, might be suitable tools for the development of new therapeutic strategies against PD
andα-synucleinopathies in general. Accordingly, conformation-specific antibodies, recently
developed against αS oligomers and fibrils, showed promising results both in cellular
and animal models [46,47], suggesting their potential assessment in clinical trials [48–50].
Such antibodies offer the indisputable advantage of specifically targeting pathogenic αS
aggregates without affecting the physiological functions of αS monomer.
5. Conclusions
Our evidence reinforces the idea that αS fibrillar aggregates can represent a fount
of harmful soluble oligomers, bearing membrane-disrupting properties. Thus, the con-
formational characterization of the pathologically relevant species using super-resolution
techniques is of fundamental importance to shed light on the molecular basis of synucle-
inopathies and provide innovative insight into rational drug development.
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